WO2020046297A2 - Peptides ayant des propriétés immuno-modulatrices - Google Patents

Peptides ayant des propriétés immuno-modulatrices Download PDF

Info

Publication number
WO2020046297A2
WO2020046297A2 PCT/US2018/048632 US2018048632W WO2020046297A2 WO 2020046297 A2 WO2020046297 A2 WO 2020046297A2 US 2018048632 W US2018048632 W US 2018048632W WO 2020046297 A2 WO2020046297 A2 WO 2020046297A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
seq
immunomodulatory
amino acid
sequence
Prior art date
Application number
PCT/US2018/048632
Other languages
English (en)
Inventor
Jesse Jaynes
Henry Wilfred Lopez
George R. Martin
Clayton Yates
Charles Garvin
Original Assignee
Riptide Bioscience, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riptide Bioscience, Inc. filed Critical Riptide Bioscience, Inc.
Priority to CN201880098522.6A priority Critical patent/CN113039194A/zh
Priority to AU2018438604A priority patent/AU2018438604A1/en
Priority to CA3110618A priority patent/CA3110618A1/fr
Priority to PCT/US2018/048632 priority patent/WO2020046297A2/fr
Priority to KR1020217008293A priority patent/KR20210052473A/ko
Priority to EP18931536.9A priority patent/EP3844297A4/fr
Priority to JP2021510646A priority patent/JP2022511280A/ja
Publication of WO2020046297A2 publication Critical patent/WO2020046297A2/fr
Priority to ZA2021/01327A priority patent/ZA202101327B/en
Priority to JP2023123680A priority patent/JP2023145635A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2018/048632 2018-08-29 2018-08-29 Peptides ayant des propriétés immuno-modulatrices WO2020046297A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201880098522.6A CN113039194A (zh) 2018-08-29 2018-08-29 具有免疫调节特性的肽
AU2018438604A AU2018438604A1 (en) 2018-08-29 2018-08-29 Peptides having immunomodulatory properties
CA3110618A CA3110618A1 (fr) 2018-08-29 2018-08-29 Peptides ayant des proprietes immuno-modulatrices
PCT/US2018/048632 WO2020046297A2 (fr) 2018-08-29 2018-08-29 Peptides ayant des propriétés immuno-modulatrices
KR1020217008293A KR20210052473A (ko) 2018-08-29 2018-08-29 면역조정 특성을 갖는 펩티드
EP18931536.9A EP3844297A4 (fr) 2018-08-29 2018-08-29 Peptides ayant des propriétés immuno-modulatrices
JP2021510646A JP2022511280A (ja) 2018-08-29 2018-08-29 免疫調節特性を有するペプチド
ZA2021/01327A ZA202101327B (en) 2018-08-29 2021-02-26 Peptides having immunomodulatory properties
JP2023123680A JP2023145635A (ja) 2018-08-29 2023-07-28 免疫調節特性を有するペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/048632 WO2020046297A2 (fr) 2018-08-29 2018-08-29 Peptides ayant des propriétés immuno-modulatrices

Publications (1)

Publication Number Publication Date
WO2020046297A2 true WO2020046297A2 (fr) 2020-03-05

Family

ID=69645844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/048632 WO2020046297A2 (fr) 2018-08-29 2018-08-29 Peptides ayant des propriétés immuno-modulatrices

Country Status (8)

Country Link
EP (1) EP3844297A4 (fr)
JP (2) JP2022511280A (fr)
KR (1) KR20210052473A (fr)
CN (1) CN113039194A (fr)
AU (1) AU2018438604A1 (fr)
CA (1) CA3110618A1 (fr)
WO (1) WO2020046297A2 (fr)
ZA (1) ZA202101327B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022034523A1 (fr) * 2020-08-13 2022-02-17 Immunitybio, Inc. Composés d'induction de phagocytose et leurs procédés d'utilisation
US11622991B2 (en) 2017-05-12 2023-04-11 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099008A1 (en) * 1999-04-26 2002-07-25 Daniel R. Twardzik Method for stimulating hematopoiesis using tgf-alpha
EP1741790A1 (fr) * 2005-03-24 2007-01-10 DIGILAB BioVisioN GmbH Methodés pour identifier et caractériser des prolyl oligopeptidases en utilisant leurs substrates et produits
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses
US20160054304A1 (en) * 2013-03-14 2016-02-25 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
CN107106638A (zh) * 2014-10-14 2017-08-29 激流生物科学有限公司 具有抗炎特性的肽
JP6964577B2 (ja) * 2015-03-23 2021-11-10 リップタイド バイオサイエンス インコーポレイテッド 抗菌性ペプチド及びその使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622991B2 (en) 2017-05-12 2023-04-11 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2022034523A1 (fr) * 2020-08-13 2022-02-17 Immunitybio, Inc. Composés d'induction de phagocytose et leurs procédés d'utilisation

Also Published As

Publication number Publication date
KR20210052473A (ko) 2021-05-10
EP3844297A4 (fr) 2022-08-31
EP3844297A2 (fr) 2021-07-07
JP2022511280A (ja) 2022-01-31
CN113039194A (zh) 2021-06-25
ZA202101327B (en) 2022-09-28
AU2018438604A1 (en) 2021-03-18
CA3110618A1 (fr) 2020-03-05
JP2023145635A (ja) 2023-10-11

Similar Documents

Publication Publication Date Title
Ahrens et al. Peptides and peptide conjugates: therapeutics on the upward path
US20190046601A1 (en) Peptides Having Anti-Inflammatory Properties
JP5253159B2 (ja) 熱応答性バイオポリマーに基づく直接的ドラッグデリバリーシステム
JP6030622B2 (ja) 癌の阻害剤としてのｍｕｃ−１細胞質ドメインペプチド
EP3059242A1 (fr) Multimère de peptides de pénétration cellulaire à hélice alpha, procédé de préparation associé et utilisation associée
CN107847583A (zh) 用于治疗癌症的聚乙二醇化白细胞介素‑10
JP2023145635A (ja) 免疫調節特性を有するペプチド
JP2013155195A (ja) 副甲状腺ホルモンを低減する治療剤
ES2879804T3 (es) Agonistas del receptor de TRAIL para el tratamiento de enfermedades fibróticas
US20130156723A1 (en) Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof
WO2021081193A1 (fr) Méthodes d'administration d'agonistes de récepteur de l'il-2
CN107108712A (zh) 提高重组蛋白产量的方法
US20210401927A1 (en) Peptides Having Immunomodulatory Properties
US20220143130A1 (en) Peptides Having Immunomodulatory Properties
US20180340020A1 (en) Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
WO2019113072A1 (fr) Peptides immunostimulants et inhibiteurs de points de contrôle, et utilisations associées dans le traitement du cancer
Kong et al. Suppression of neovascularization and experimental arthritis by D-form of anti-flt-1 peptide conjugated with mini-PEG™
JP2010509241A (ja) 膜貫通ペプチドからなる自己凝集性ナノ粒子および抗癌剤の特異的腫瘍内送達のためのその利用
JP2011102322A (ja) 毒性が低下したｔｎｆファミリーのリガンド、リガンドのアゴニストの投与方法
JP2020501513A (ja) 治療用多標的コンストラクトおよびその使用
US20170246311A1 (en) Peptides for binding alternatively activated macrophages
US20170029481A1 (en) Compounds That Bind to the Erythropoietin Receptor
WO2023097111A2 (fr) Méthodes et compositions pour traiter des afffections associées à une calcinose
JP4566406B2 (ja) Ｇｉｔ輸送受容体を標的とするレトロ反転ペプチド及び関連する方法
US20220213165A1 (en) Therapeutic peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18931536

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3110618

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021510646

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018438604

Country of ref document: AU

Date of ref document: 20180829

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20217008293

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018931536

Country of ref document: EP

Effective date: 20210329